First programme to assess potential cardiovascular and renal benefit of an SGLT-2i beyond diabetes
AstraZeneca today announced two new randomised, placebo-controlled Phase IIIb outcome trials with Forxiga (dapagliflozin), an SGLT-2 inhibitor currently indicated for the treatment of type-2 diabetes. These two large outcome trials will help to define the potential role of dapagliflozin in the management of chronic kidney disease and chronic heart failure respectively, in people with and without type-2 diabetes.
This marks the first time a major outcome trial will be conducted to evaluate the effect of an SGLT-2 inhibitor in chronic kidney disease, for which there are currently few treatment options and a significant unmet medical need.1,2
AstraZeneca today also announced the initiation of a series of new mechanistic trials designed to understand the underlying science behind the potential cardiovascular and renal protective signals seen with the SGLT-2 inhibitor class.
These new trials reinforce AstraZeneca’s commitment to Cardiovascular and Metabolic disease (CVMD) as one of its main therapy areas and to dapagliflozin, for which the body of evidence continues to growwith more than 80 completed and ongoing clinical trials and more than a million patients treated to date.
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, said: “Our transformative clinical research aims to address the multiple risk factors associated with cardiovascular morbidity and mortality, including diabetes, chronic heart failure and chronic kidney disease. By following the science, we are seeking to improve outcomes for millions of patients with cardiovascular disease around the world.”
Professor John McMurray, Professor of Cardiology at the Institute of Cardiovascular and Medical Sciences, University of Glasgow, and a member of the Executive Committee for both the chronic heart failure and chronic kidney disease trials, said: “This partnership between AstraZeneca and the wider clinical community is of great importance in allowing us to investigate the potential benefits of dapagliflozin in chronic heart failure and chronic kidney disease, and potentially to transform the way we view and manage these two conditions which place such a burden on our patients and health care systems.”
There are currently an estimated 200 million people worldwide currently living with chronic kidney disease,1 and 38 million people living with chronic heart failure.2
NOTES TO EDITORS
About SGLT-2 inhibitors
Dapagliflozin (marketed as Farxiga in the US and Forxiga outside the US) is part of a class of medicines called sodium-glucose cotransporter 2 (SGLT-2) inhibitors used to manage type-2 diabetes, which remove glucose via the kidneys.
About AstraZeneca in Cardiovascular and Metabolic Disease (CVMD)
Cardiovascular, renal and metabolic diseases are key areas of focus for AstraZeneca as part of the company’s strategy for achieving scientific leadership and returning to growth. By collaborating across therapeutic disciplines as part of the CVMD therapy area, we are addressing the multiple risk factors associated with CVMD, with the goal of reducing morbidity, mortality and organ damage through innovative therapies. Recognising the growing unmet need and challenges faced by the millions of people across the world living with these interrelated diseases, we’re determined to understand how they interact and impact one another – and how they can be treated together to save more patients’ lives.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Neil Burrows||UK/Global||+44 203 749 5637|
|Vanessa Rhodes||UK/Global||+44 203 749 5736|
|Karen Birmingham||UK/Global||+44 203 749 5634|
|Rob Skelding||UK/Global||+44 203 749 5821|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Craig Marks||Finance, Fixed Income, M&A||+44 7881 615 764|
|Nick Stone||Respiratory & Autoimmunity||+44 203 749 5716|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Christer Gruvris||Infection & Neuroscience||+44 203 749 5711|
|Lindsey Trickett||Cardiovascular & Metabolic Diseases||+1 240 543 7970|
|Mitchell Chan||Oncology||+1 240 477 3771|
|Toll free||+1 866 381 7277|
1Ojo A. “Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translation Research.” Transactions of the American Clinical And Climatological Association. 2014; 125:229-246.
2Eugene Braunwald. The war against heart failure: the Lancet lecture. The Lancet. 2015; 385: 812–24.